Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.
Valuation and Earnings
This table compares Monte Rosa Therapeutics and Arbutus Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | $28.73 million | 42.38 | -$38.63 million | ($1.76) | -8.11 |
| Arbutus Biopharma | $14.08 million | 72.88 | -$33.50 million | $0.79 | 6.56 |
Institutional & Insider Ownership
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Monte Rosa Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Monte Rosa Therapeutics and Arbutus Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| Arbutus Biopharma | 0 | 1 | 1 | 0 | 2.50 |
Monte Rosa Therapeutics currently has a consensus price target of $28.50, suggesting a potential upside of 99.72%. Arbutus Biopharma has a consensus price target of $5.00, suggesting a potential downside of 3.47%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Arbutus Biopharma.
Profitability
This table compares Monte Rosa Therapeutics and Arbutus Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
| Arbutus Biopharma | 84.22% | 90.98% | 82.34% |
Summary
Arbutus Biopharma beats Monte Rosa Therapeutics on 8 of the 15 factors compared between the two stocks.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
